Nkarta, Inc. (NKTX) Market Cap
Nkarta, Inc. has a market capitalization of $239.3M.
Financials based on reported quarter end 2025-12-31
Price: $3.36
▼ -0.13 (-3.84%)
Market Cap: 239.25M
NASDAQ · time unavailable
CEO: Paul J. Hastings
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2020-07-10
Website: https://www.nkartatx.com
Nkarta, Inc. (NKTX) - Company Information
Market Cap: 239.25M · Sector: Healthcare
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Analyst Sentiment
Based on 12 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 2 sources)
Consensus Price Target
Low
$15
Median
$16
High
$36
Average
$22
Potential Upside: 543.6%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"NKTX reported 2025 revenue of $0 (reported), with net income of -$27.4M and EPS of -$0.37. Net margin is therefore negative, and the company remains loss-making based on the most recent quarter/year figure provided. Free cash flow was also negative at -$22.2M, driven by operating cash flow of -$21.6M despite modest capex of -$0.6M, indicating cash burn is not being offset by operating generation. On the balance sheet (2025-12-31), NKTX had $404.2M in assets versus $91.9M in liabilities, with equity of $312.3M and net debt of ~$36.8M—suggesting more equity cushion than leverage-driven risk, though ongoing losses keep pressure on cash needs. Valuation data is limited because market cap and P/E/FCF yield were not provided; however, the stock price is $2.14 and has strong momentum, with a +56.2% 1-year gain. Dividends are $0 and there are no buyback figures provided, so shareholder returns have been dominated by capital appreciation rather than distributions."
Revenue Growth
Revenue was reported as $0 for the period provided, leaving no basis to assess growth or commercial traction from these figures.
Profitability
Net income was -$27.4M with EPS of -$0.37, indicating persistently negative profitability and limited efficiency metrics to support improvement.
Cash Flow Quality
Free cash flow was negative at -$22.2M, with operating cash flow of -$21.6M; capex was modest, but cash burn is present. No dividends were paid.
Leverage & Balance Sheet
Net debt of ~$36.8M is modest relative to equity of $312.3M; assets of $404.2M exceed liabilities of $91.9M, providing balance sheet cushion despite ongoing losses.
Shareholder Returns
Total shareholder value creation (as observable) is driven by price appreciation: the stock is up 56.2% over 1 year. Dividends and buybacks are not evidenced in the dataset.
Analyst Sentiment & Valuation
Analyst consensus target is ~$21.6 versus a $2.14 current price, implying expectations for upside, but core valuation ratios (P/E, FCF yield) were not provided for validation.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.